.Pharmacolibrary.Drugs.ATC.L.L01XK05 .Pharmacolibrary.Drugs.ATC.L.L01XK05| name: | Veliparib |
| ATC code: | L01XK05 | route: | oral |
| n-compartments | 1 |
Veliparib (ATC code L01XK05) is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, used primarily in oncology as a targeted therapy for cancers such as ovarian and breast cancer, particularly in patients with BRCA mutations. Veliparib is not broadly approved as a monotherapy but has been investigated in combination with DNA-damaging chemotherapies in clinical trials.
Pharmacokinetic parameters in adult patients with advanced solid tumors (mainly ovarian or BRCA-associated breast cancer) after single oral administration, median age 54, mixed sex.
Singh, R, et al., & Beumer, JH (2019). Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer chemotherapy and pharmacology 83(2) 319–328. DOI:10.1007/s00280-018-3731-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30456480
Stodtmann, S, et al., & Xiong, H (2021). A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. Journal of clinical pharmacology 61(9) 1195–1205. DOI:10.1002/jcph.1875 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33894017
Salem, AH, et al., & Mostafa, NM (2014). Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clinical pharmacokinetics 53(5) 479–488. DOI:10.1007/s40262-013-0130-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24452810